BRISBANE, Calif.--(BUSINESS WIRE)--
Innoviva, Inc. (NASDAQ: INVA) announced today that Michael W.
Aguiar, Innoviva's President and Chief Executive Officer will present at
the 2017 Cowen Health Care Conference in Boston on March 7 at 9:20 a.m.
A live webcast of the presentation can be found at: http://wsw.com/webcast/cowen38/inva.
The webcast will also be archived for 90 days.
Innoviva is focused on bringing compelling new medicines to patients in
areas of unmet need by leveraging its significant expertise in the
development, commercialization and financial management of
bio-pharmaceuticals. Innoviva's portfolio is anchored by the respiratory
assets partnered with Glaxo Group Limited (GSK), including RELVAR®/BREO®
ELLIPTA® and ANORO® ELLIPTA®, which were jointly developed by Innoviva
and GSK. Under the agreement with GSK, Innoviva is eligible to receive
associated royalty revenues from RELVAR®/BREO® ELLIPTA®, ANORO®
ELLIPTA®. In addition, Innoviva retains a 15 percent economic interest
in future payments made by GSK for earlier-stage programs partnered with
Theravance BioPharma, Inc., including the closed triple combination
therapy for COPD. For more information, please visit Innoviva's website
ANORO®, RELVAR®, BREO® and ELLIPTA® are trademarks of the
GlaxoSmithKline group of companies.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170228005387/en/
Senior Vice President and Chief
Source: Innoviva, Inc.
News Provided by Acquire Media